Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Oncology and Rare Disease Development.
TarMart Solution Ecosystem & Related Targets
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT & Mutant) | BCAT2 Recombinant Proteins (WT & Catalytic Dead Mutant E243A/K256A). High purity (>95%), Endotoxin <1 EU/µg. Sequence verified, HEK293 expressed, mitochondrial isoform with native conformation. WT suitable for transamination kinetics; mutant ideal for negative control. | View BCAT2 Products |
| Benchmark Antibody | Anti-BCAT2 Recombinant Antibody. Sequence-defined rabbit monoclonal for Western blot, IHC, and cellular target engagement. | View BCAT2 Products |
| Gene Delivery | BCAT2 Premade ORF / Lentivirus. Full-length ORF (CMV promoter) for stable cell line construction and metabolomic flux studies. | View BCAT2 Products |
| Validator | BCAT2 siRNA Set (3 targets + control). For knockdown verification and specificity profiling in BCAA metabolism assays. | View BCAT2 Products |
| Related Target A: BCAT1 | BCAT1 (Cytosolic Isoform) Recombinant Protein. 43% sequence identity; essential for isoform selectivity counter-screening. Purity >95%, sequence verified. | View BCAT1 Products |
| Related Target B: SLC7A5 (LAT1) | BCAA membrane transporter recombinant protein (ECD-Fc fusion). Synergistic target for complete BCAA pathway blockade. | View SLC7A5 Products |
| Related Target C: BCKDK | Branched-Chain Ketoacid Dehydrogenase Kinase recombinant protein. Downstream regulatory node; synergistic pathway partner for combination therapy. | View BCKDK Products |
Critical Assay Challenges
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (BCAT1 vs BCAT2) | High-purity homologous proteins (BCAT1 and BCAT2) >95% purity, verified by mass spectrometry. Ortholog pair enables clean SAR and selectivity panels. |
| Mitochondrial Enzyme Activity Validation | Active WT protein with validated PLP cofactor binding site. Suitable for transamination kinetics and inhibitor mechanism studies (competitive vs allosteric). |
| False Positives in Metabolic Screens | Catalytic-dead mutant (E243A/K256A) included as negative control to distinguish specific inhibition from assay artifacts. |
| Cross-species Evaluation | Human, Mouse, Cynomolgus BCAT2 ortholog proteins available with theoretical MW confirmation and endotoxin control. |
| Cellular Context Validation | BCAT2 Lentivirus and validated siRNA bundle for orthogonal target validation and intracellular metabolomics (BCAA flux, mTOR signaling). |
Live BCAT2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active Clinical Trials
- Latest Metabolic Reprogramming Research
- Latest Resistance Research
- Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for BCAT2 therapeutics is intensifying as the industry recognizes the critical role of mitochondrial branched-chain amino acid (BCAA) metabolism in driving tumor progression, immune evasion, and ferroptosis resistance. BCAT2 (mitochondrial isoform) has emerged as a vulnerability in solid tumors, particularly triple-negative breast cancer (TNBC), glioblastoma (GBM), and pancreatic ductal adenocarcinoma (PDAC), where it drives leucine-dependent mTOR activation and TCA cycle anaplerosis. Unlike the cytosolic BCAT1 (primarily hematologic malignancies), BCAT2 inhibition shows synthetic lethality with glutaminase (GLS) inhibitors, positioning it as a cornerstone for combination metabolic therapies. As first-generation small molecule inhibitors enter preclinical development, the next wave of R&D is targeting allosteric sites, PROTAC-mediated degradation, and enhanced brain penetration for GBM indications. Dual BCAT1/BCAT2 inhibition strategies are also being explored in KRAS-mutant and IDH-mutant malignancies. The field is shifting from broad metabolic poisons to highly selective isoform inhibitors and combination regimens with immunotherapy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Preclinical Discovery Programs & Metabolic Oncology Biotechs | Solid Tumors (TNBC, GBM, PDAC, NSCLC), Metabolic Syndrome | Isoform Selectivity Assay (Need BCAT1 vs BCAT2 WT/Mutant Proteins) |
| PROTAC / Degrader | Targeted Protein Degradation Innovators & Academic Centers | Refractory Solid Tumors (BCAA-addicted) | Cellular Validation: Lentivirus & siRNA for target engagement; Ternary Complex Assay (tag-optimized proteins) |
| RNAi / ASO | Gene Therapy Companies | Metabolic Disorders, Solid Tumors | Knockdown Validation (Need Sequence-verified siRNA and control Abs) |
| Metabolic Synergy Combo | Metabolic Pathway Consortia & Oncology Pharma | Refractory Tumors, Immuno-Oncology | Pathway Panel (BCAT2 + BCKDK + SLC7A5 recombinant proteins) |